Delve into the landscape of biotech companies developing treatments for HIV and find out if we are getting closer to a cure.

Benjamin Chen, MD, PhD, of the Icahn School of Medicine at Mount Sinai, discusses the implications of his new study involving ...

Benjamin K. Chen, MD, PhD, discussed the next steps after the results of his study in genetic tagging showed promise in ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these immune proteins can do more than that: They also activate other components of ...

Nevertheless, an estimated 2.6 million people were newly infected in 2009. HIV infects vital cells in the human immune system such as helper T cells (specifically CD4+ T cells), macrophages ...

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV ...

As an HIV researcher for many years, I want to address Dr. Neal Barnard’s dismissive claims in his op-ed in The ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Antibodies are best known for their ability to latch onto and neutralize bacteria, viruses and other pathogens. But these ...

As a result, some HIV-infected cells escape and lay dormant for decades, possibly coming to the surface if medication is interrupted. Miliotis’ presentation, “Finding HIV: A Swipe in the Right ...

Mar. 19, 2025 — New study demonstrates how high-affinity B cells 'bank' their ... organ from donors who are also HIV positive as it is from donors who are not infected with the ...